Actively Recruiting
Validation of a miRNA Panel to Optimize Treatment Response in Patients With Metastatic Pancreatic Cancer (mirPANC 2)
Led by Benedito Mauro Rossi · Updated on 2025-04-27
60
Participants Needed
1
Research Sites
149 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is being conducted to better understand how pancreatic cancer behaves during treatment and how we can improve methods for monitoring disease progression. The research aims to determine whether small molecules present in the blood, called miRNAs, can help doctors assess whether the treatment is working or needs adjustment. With this, we hope to make cancer monitoring less invasive and more precise, allowing patients to receive more personalized and effective treatments.
CONDITIONS
Official Title
Validation of a miRNA Panel to Optimize Treatment Response in Patients With Metastatic Pancreatic Cancer (mirPANC 2)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients diagnosed with metastatic PDAC
- Patients who will start treatment with FOLFIRINOX
- 18 years or older
- Agree to participate by signing the Informed Consent Form
You will not qualify if you...
- Previous chemotherapy treatment, including neoadjuvant, adjuvant, or first-line therapy
- Not eligible for FOLFIRINOX due to hyperbilirubinemia or poor performance status related to age or health
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
A Beneficência Portuguesa de São Paulo
São Paulo, São Paulo, Brazil
Actively Recruiting
Research Team
C
Camila Farias
CONTACT
B
Bianca Verboski
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here